Minerva Neurosciences, Inc. (NASDAQ:NERV) Short Interest Update

Minerva Neurosciences, Inc. (NASDAQ:NERV) was the target of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 23,400 shares, a growth of 229.6% from the October 31st total of 7,100 shares. Based on an average trading volume of 16,100 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.4% of the shares of the company are sold short.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. StockNews.com assumed coverage on Minerva Neurosciences in a report on Tuesday. They issued a “sell” rating for the company. HC Wainwright restated a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Trading Down 0.9 %

Shares of Minerva Neurosciences stock traded down $0.02 during trading on Wednesday, hitting $2.15. The stock had a trading volume of 26,674 shares, compared to its average volume of 51,652. The firm has a market cap of $15.03 million, a price-to-earnings ratio of -4.89 and a beta of 0.18. Minerva Neurosciences has a 12 month low of $2.07 and a 12 month high of $13.49. The business’s 50-day moving average is $2.48 and its 200 day moving average is $2.77.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.